Get to commercial scale years earlier than your balance sheet allows.

Yes. The early-stage startup tier exists for exactly that, at $25,000 with no capacity commitment and no minimum size of process, and it still gets you into all four working groups, the results of every joint study, and vessel access at cost plus. You move up a stage at renewal as the company grows, so the fee tracks where you actually are rather than where you hope to be. If even that is out of reach right now, there are a small number of in-kind places each year for companies that contribute work instead of cash. The details are at the end of the producing member tiers.

No. There is no reporting obligation and no shared database of member runs. Nobody is asked to hand over process records, cell lines or product data. What we do ask is that you bring your experience to the working groups, so the group is not paying to rediscover something a member already knows. Know-how offered freely is a different thing from data surrendered contractually, and only the first is expected here.

Your fee, your people, and your experience. The whole point of the group is that nobody re-runs an experiment somebody else has already run. Members are expected to turn up, engage seriously with the technical agenda, and share what they have learned so the field moves faster than any of us could alone. If contributing hard-won know-how to help the industry is not something you want to do, this is not the right room for you. Hosting a jointly funded campaign at your site is welcome but optional, and is reimbursed at cost plus.

Not on that basis alone. Membership requires that plant cells are genuinely your problem, either because you run plant cell processes or because you supply the equipment, engineering or services those companies depend on. The reason is practical rather than precious: plant cells grow in days rather than hours, in aggregates rather than free suspension, and the product is frequently the biomass itself. A working group that has to translate every discussion back to yeast spends its time translating instead of solving.

Pre-competitive collaboration is well established in industrial biotechnology, but the scope has to be drawn carefully. The consortium charter is reviewed under EU and US competition law, and the agenda excludes pricing, customers, market allocation and output decisions. Technical scope only.

Because almost nothing is being built from scratch. The site is brownfield, so the building, utilities and permits already exist. The vessels are bought from decommissioned food-grade plants and relocated, which avoids the fabrication queue that is usually the longest single item on a schedule like this. Installation, piping, instrumentation and qualification still have to be done, and that is a substantial job, but it is a fraction of the cost and the years that fabricating and building the same capacity would take. As with anything worth doing, there is risk in it, and we will not pretend otherwise. What we will say is that the founding members are committed to making this work, and that the whole structure of the group, shared capital, shared engineering and shared capacity, exists to make the date more likely rather than less.